The cutting-edge weight loss and diabetes research developed by medicinal chemist Robert Doyle has offered significant and consistent weight loss and glucose control to its recipients through peptide-based treatments. Doyle and his fellow collaborators reported that two new peptide compounds—GEP44 and KCEM1—considerably reduce body weight and normalize blood glucose levels without causing the typical negative side effects experienced by patients who take currently available GLP-1-based anti-obesity drugs. Doyle, the Jack and Laura H. Milton Professor and Dean's Professor of Chemistry in the College of Arts and Sciences,focuses his research on pharmaceutical drug development for the treatment of obesity and type 2 diabetes. On this episode, Doyle discusses his breakthrough weight loss research, the important role students play in advancing his research, and how, through philanthropy, his work has come to life.
